Cargando…
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
OBJECTIVES: To evaluate efficacy and safety of abatacept in adults with active primary Sjögren’s syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial. METHODS: Eligible patients (moderate-to-severe pSS [2016 ACR/European League Against Rheumatism (EULAR) criteria], EULAR...
Autores principales: | Baer, Alan N, Gottenberg, Jacques-Eric, St Clair, E William, Sumida, Takayuki, Takeuchi, Tsutomu, Seror, Raphaèle, Foulks, Gary, Nys, Marleen, Mukherjee, Sumanta, Wong, Robert, Ray, Neelanjana, Bootsma, Hendrika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892395/ https://www.ncbi.nlm.nih.gov/pubmed/33168545 http://dx.doi.org/10.1136/annrheumdis-2020-218599 |
Ejemplares similares
-
Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022) -
Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019) -
Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022) -
Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019) -
Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)